Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?

Zacks09-27

Profound Medical (PROF) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2470017507?lang=en_US&edition=fundamental","thumbnail":"https://s.yimg.com/uu/api/res/1.2/Wv2ctYy6p_JVpbsnztsiWw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c0b5ef86c346fee33163b54006e5e04c","is_english":true,"pubTime":"2024-09-27 17:27","share_image_url":"https://static.laohu8.com/5f26f4a48f9cb3e29be4d71d3ba8c038","id":"2470017507","market":"us","top_or_hot":-1,"title":"Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?","media":"Zacks","content":"<div>\n<p>Profound Medical (PROF) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical...</p>\n\n<a href=\"https://finance.yahoo.com/news/profound-medical-prof-moves-5-092700904.html\">Source Link</a>\n\n</div>\n","source":"yahoofinance","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Profound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nProfound Medical (PROF) Moves 5.1% Higher: Will This Strength Last?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-09-27 17:27 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://finance.yahoo.com/news/profound-medical-prof-moves-5-092700904.html><strong>Zacks</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Profound Medical (PROF) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical...</p>\n\n<a href=\"https://finance.yahoo.com/news/profound-medical-prof-moves-5-092700904.html\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PROF","symbol_name":"Profound Medical Corp.","start_time":0,"source_url":"https://finance.yahoo.com/news/profound-medical-prof-moves-5-092700904.html","article_id":"2470017507","we_media_id":null,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/Wv2ctYy6p_JVpbsnztsiWw--~B/aD01OTQ7dz05MDA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/c0b5ef86c346fee33163b54006e5e04c"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2470017507","pubTimestamp":1727429220,"sourceInfo":{"source_id":"yahoofinance","name":"雅虎金融"},"weMediaInfo":null,"summary":"Profound Medical  shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.2% loss over the past four weeks.The sudden surge in share price can be attributed to positive investor expectations from Profound’s lead marketed product, the Tulsa-Pro system, which is approved for the ablation of prostate tissue. In July 2024, the U.S. Centers for Medicare & Medicaid Services proposed a reimbursement rule under the outpatient prospective payment system for three new CPT Category 1 codes related to the TULSA procedure. The final rule is expected in November 2024 and will take effect on January 1, 2025. An early-stage study is currently comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer. Profound expects to report interim data from this post-market study in the first half of 2025.Profound Medica","collect":0,"end_time":0,"defaultTopTitle":"yahoo.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"PROF":"Profound Medical Corp.","BK4532":"文艺复兴科技持仓","BK4183":"个人用品","USNA":"优莎娜","BK4082":"医疗保健设备"},"translate_title":"Profound Medical(PROF)上涨5.1%：这种强势会持续吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PROF":1,"USNA":0.9},"content_text":"Profound Medical (PROF) shares rallied 5.1% in the last trading session to close at $7.85. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 17.2% loss over the past four weeks.\nThe sudden surge in share price can be attributed to positive investor expectations from Profound’s lead marketed product, the Tulsa-Pro system, which is approved for the ablation of prostate tissue. In July 2024, the U.S. Centers for Medicare & Medicaid Services proposed a reimbursement rule under the outpatient prospective payment system for three new CPT Category 1 codes related to the TULSA procedure. The final rule is expected in November 2024 and will take effect on January 1, 2025. An early-stage study is currently comparing the TULSA procedure to radical prostatectomy in men with localized prostate cancer. Profound expects to report interim data from this post-market study in the first half of 2025.\nThis company is expected to post quarterly loss of $0.31 per share in its upcoming report, which represents a year-over-year change of -19.2%. Revenues are expected to be $3.27 million, up 88.8% from the year-ago quarter.\nWhile earnings and revenue growth expectations are important in evaluating the potential strength in a stock, empirical research shows a strong correlation between trends in earnings estimate revisions and near-term stock price movements.\nFor Profound Medical, the consensus EPS estimate for the quarter has remained unchanged over the last 30 days. And a stock's price usually doesn't keep moving higher in the absence of any trend in earnings estimate revisions. So, make sure to keep an eye on PROF going forward to see if this recent jump can turn into more strength down the road.\nThe stock currently carries a Zacks Rank #3 (Hold). You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>>\nProfound Medical is part of the Zacks Medical - Drugs industry. USANA Health Sciences (USNA), another stock in the same industry, closed the last trading session 3.6% higher at $37.83. USNA has returned -9.6% in the past month.\nFor USANA Health , the consensus EPS estimate for the upcoming report has remained unchanged over the past month at $0.49. This represents a change of -17% from what the company reported a year ago. USANA Health currently has a Zacks Rank of #3 (Hold).\nWant the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report\nProfound Medical (PROF) : Free Stock Analysis Report\nUSANA Health Sciences, Inc. (USNA) : Free Stock Analysis Report\nTo read this article on Zacks.com click here.\nZacks Investment Research","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2470017507"}